Inclusion Criteria:

• Disease Related

  • Histologically or cytologically confirmed adenocarcinoma of the stomach, gastroesophageal junction or distal esophagus with metastatic disease
  • Measurable or non-measurable disease per RECIST Guidelines

• Demographic

  •18 years of age or older at the time the written informed consent is obtained

• General

  • Able to swallow oral medication
  • ECOG performance status of 0 or 1

• Laboratory

  • Adequate organ and hematological function as evidenced by laboratory studies prior to randomization

Exclusion Criteria:

• Disease Related

  • Prior chemotherapy for metastatic disease (1st line)
  • Less than 12 months have elapsed from completion of previous adjuvant or neoadjuvant chemotherapy or chemoradiotherapy
  • Subjects with persistent gastric outlet obstruction, complete dysphagia or feeding jejunostomy
  • Current or prior history of central nervous system metastases
  • History of bleeding diathesis or clinically significant bleeding within 14 days prior to randomization
  • Major surgical procedure within 28 days prior to randomization
  • Minor surgical procedure, placement of access device or fine needle aspiration within 7 days prior to first dose
  • Prior malignancy (other than in situ cervical cancer, or basal cell cancer of the skin) unless treated with curative intent and without evidence of disease for ≥ 3 years prior to randomization
  • Clinically significant cardiovascular diseases within 12 months prior to randomization
  • Presence of clinically significant non-healing wound, ulcer or fracture as judged by the investigator
  • Ongoing or clinically significant active infection as judged by the investigator
  • Known hypersensitivity to bacterial proteins, or any of the drugs required in this study
  • Known peripheral neuropathy ≥Grade 1
  • Known dihydropyrimidine dehydrogenase deficiency
  • Known hypersensitivity to 5-FU/capecitabine
  • Known positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B surface antigen
  • Known active or chronic hepatitis

• Medications

  • Currently or previously treated with angiopoietin inhibitors, or inhibitors of TIE-1 or TIE-2
  • Treatment with immune modulators such as cyclosporine or tacrolimus within 30 days prior to randomization
  • Treatment with sorivudine or its chemically related analogues
  • Anticoagulants (other than aspirin) including coumarin-type anticoagulants within 7 days prior to randomization

• General

  • Not yet completed at least 30 days since ending other investigational device/drug trial(s), or subject is receiving other investigational treatments
  • Pregnant or is breast feeding